[144] Zepp Health Corp SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Zepp Health Corp (ZEPP) reports a proposed sale of 3,000 American Depositary Receipts (ADRs) by a person who acquired them as founder shares on 02/08/2018 from the issuer. The filer plans to sell the ADRs through Piper Sandler & Co. on the NYSE, with an aggregate market value listed at $133,590 and an approximate sale date of 09/29/2025.

The filing states there were no other securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The number of ADRs outstanding is reported as 14,591,331, providing context for the size of the proposed sale relative to total shares.

Insights

Securities Analyst

TL;DR: Small founder sale disclosed; insufficient to move valuation or signal material change.

The proposed sale of 3,000 ADRs valued at $133,590 is explicitly recorded as founder shares acquired from the issuer in February 2018 and to be executed via Piper Sandler on the NYSE on 09/29/2025. With 14,591,331 ADRs outstanding, this block represents a very small fraction of outstanding shares. The filing contains no prior 3-month sales by the seller and includes the standard representation about material undisclosed information. From an investor-impact perspective, this is a routine insider liquidity event and not a material corporate development.

Corporate Governance Expert

TL;DR: Routine disclosure of insider sale; governance controls appear followed.

The document meets Rule 144 disclosure by specifying acquisition date, nature (founder shares), broker, planned sale date, and aggregate value. The seller affirms lack of undisclosed material information and reports no other recent sales. There is no indication of unusual timing, large share concentration, or governance concerns within this notice alone. This filing should be viewed as administrative compliance rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADRs	Piper Sandler & Co Inc 350 N 5th St Minneapolis MN 55401	3000	133590.00	14591331	09/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADRs	02/08/2018	Founders Shares	Issuer			3000	02/18/2018	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Zepp Health Corp's (ZEPP) Form 144 disclose?

The Form 144 discloses a proposed sale of 3,000 ADRs valued at $133,590, to be executed via Piper Sandler on NYSE around 09/29/2025.

When were the ADRs acquired that are being sold under the ZEPP Form 144?

The ADRs were acquired as founder shares on 02/08/2018 from the issuer, with payment dated 02/18/2018.

How large is the proposed sale relative to ZEPP's outstanding ADRs?

The filing lists 14,591,331 ADRs outstanding; the proposed 3,000 ADR sale is a very small fraction of total outstanding shares.

Did the filer report any securities sold in the past three months for ZEPP?

The Form 144 states "Nothing to Report" for securities sold during the past three months by the seller.

Does the Form 144 indicate any undisclosed material information about ZEPP?

By signing, the seller represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.